Want to see DRTS full AI Analyst Report?
DRTS Stock Chart & Stats
$14.96
-$0.12(-0.96%)
At close: 4:00 PM EDT
$14.96
-$0.12(-0.96%)
Day’s Range― - ―
52-Week Range$3.35 - $15.10
Previous CloseN/A
Volume333.05K
Average Volume (3M)609.06K
Market Cap
$1.27B
Enterprise Value$1.05K
Total Cash (Recent Filing)$100.64M
Total Debt (Recent Filing)$15.15M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 24, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding90,325,874
10 Day Avg. Volume748,471
30 Day Avg. Volume609,060
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside-8.65% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$1.23M
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressFDA clearance to resume enrollment, add two academic centers and advance REGAIN materially strengthens the clinical and regulatory pathway. Early efficacy and safety signals could support broader adoption if confirmed in the remaining patients and larger studies.
Strategic Commercial PartnershipThe Tolmar agreement provides experienced U.S. commercial infrastructure, manufacturing funding and milestone support. This reduces the burden of building a sales network alone and creates a potentially durable route to commercialization in urological oncology.
Moderate Financial LeverageRelative to its equity base, Alpha Tau carries moderate debt, limiting current interest and refinancing pressure compared with a highly leveraged development company. Positive equity since 2022 provides a stronger base for funding clinical and manufacturing plans.
Bears Say
No Commercial RevenueZero reported revenue shows Alpha DaRT remains pre-commercial and dependent on clinical, regulatory and manufacturing execution before generating product sales. This leaves the business exposed to delays and means current operations lack an established recurring revenue base.
Persistent Losses And Cash BurnWidening losses and sustained operating and free-cash-flow deficits indicate that clinical development continues to consume substantial capital. Without a timely commercial revenue ramp, the company will likely need ongoing external funding to sustain operations.
Financing And Dilution RiskFuture capital-raising flexibility is important for a cash-burning company, but additional equity issuance could dilute existing holders. The combination of persistent losses, negative cash flow and registered share capacity keeps funding risk material over the next several quarters.
Alpha Tau News
DRTS FAQ
What was Alpha Tau’s price range in the past 12 months?
Alpha Tau lowest stock price was $3.35 and its highest was $15.10 in the past 12 months.
What is Alpha Tau’s market cap?
Alpha Tau’s market cap is $1.27B.
When is Alpha Tau’s upcoming earnings report date?
Alpha Tau’s upcoming earnings report date is Nov 24, 2026 which is in 82 days.
How were Alpha Tau’s earnings last quarter?
Alpha Tau released its earnings results on Aug 10, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.141 by -$0.359.
Is Alpha Tau overvalued?
According to Wall Street analysts Alpha Tau’s price is currently Overvalued.
Does Alpha Tau pay dividends?
Alpha Tau does not currently pay dividends.
What is Alpha Tau’s EPS estimate?
Alpha Tau’s EPS estimate is -0.14.
How many shares outstanding does Alpha Tau have?
Alpha Tau has 90,325,874 shares outstanding.
What happened to Alpha Tau’s price movement after its last earnings report?
Alpha Tau reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.141. Following the earnings report the stock price went up 4.926%.
Which hedge fund is a major shareholder of Alpha Tau?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.67 (-8.65% Downside)
$13.67 (-8.65% Downside)
Blogger Sentiment
Bullish
DRTS Sentiment 87%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
308.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alpha Tau
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$13.67
▼(-8.65% Downside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.10% Insiders
0.08% Mutual Funds
4.94% Other Institutional Investors
94.64% Public Companies and
Individual Investors